CagriSema: when can you actually buy it?
You cannot, and this page exists to say so with a date rather than a shrug. CagriSema is cagrilintide and semaglutide combined in one weekly injection, pairing an amylin analogue with a GLP-1, developed by Novo Nordisk, and it holds no approved application in the United States. Every other page on this site carries a price; this one carries the only public schedule there is instead — the phase 3 trial programme.
When will CagriSema be available, and what will it cost?
No date has been published by anyone, and no price exists because nothing is for sale. What is public is the trial programme, and it sets a floor. CagriSema has 12 phase 3 trials in obesity or overweight registered on ClinicalTrials.gov, enrolling 10,594 people between them, the largest of them 3,400. 5 have completed and 7 are still running, with the last reaching primary completion in 2030-03-20. A sponsor can file on part of a programme rather than wait for the whole of it, so these dates bound the earliest plausible approval rather than predicting one. Drugs@FDA was checked on 2026-08-28 and holds no application for this molecule, against six for semaglutide — the absence is a finding, not a lookup failure.
The trial programme
| Sponsor | Novo Nordisk |
|---|---|
| Approved in the US | no — no application in Drugs@FDA |
| Phase 3 trials in obesity or overweight | 12 |
| Completed | 5 of 12 |
| Still running | 7 |
| Participants enrolled across them | 10,594 |
| Largest single trial | 3,400 participants |
| Last primary completion | 2030-03-20 |
Counted from ClinicalTrials.gov on 2026-08-28, restricted to phase 3 studies whose registered condition is obesity, overweight or weight. Approval status checked against Drugs@FDA the same day.
What is worth knowing now
CagriSema is half a drug you can already buy: semaglutide is approved and sold, and it is what Wegovy and Ozempic are. What is not approved is the pairing with cagrilintide, and the combination is regulated as its own product rather than as semaglutide with something added — which is why no part of it can be bought early. It carries the biggest programme of the three, twelve phase 3 trials in obesity or overweight enrolling 10,594 people, and also the longest tail: six are still running and the last reaches primary completion in March 2030.
CagriSema, answered
- Is CagriSema FDA approved?
- No. Drugs@FDA holds no approved application for it, checked on 2026-08-28. That check is worth stating precisely because the same query returns six applications for semaglutide, so the absence is a real answer rather than a failed search. Until an application is approved there is no legal route to buy it in the United States outside a clinical trial, at any price.
- When will CagriSema be available?
- Nobody has published a date, and the honest floor comes from the trials rather than from a press release. 7 of its 12 phase 3 trials in obesity or overweight are still running, and the last reaches primary completion in 2030-03-20. A company can file on part of a programme rather than wait for all of it, so that is a floor and not a forecast — but it does rule out the near term.
- What does CagriSema cost?
- Nothing, because it cannot be bought. There is no list price, no cash price and no savings programme, and any figure circulating is either a forecast or an invention. When it is approved and sold, it will get a card on this site with the price read from the seller's own page and the date it was read, the same as everything else here.
- Semaglutide is approved. Why can't I just take that with cagrilintide?
- Because cagrilintide on its own is not approved either, and a combination is assessed as a new product with its own trials rather than as the sum of two prescriptions. What you can do today is take semaglutide, which is approved, sold, and priced on this site under Wegovy and Ozempic. What the trials are testing is whether the pairing beats it by enough to matter — a question the published results will settle and this page will not pre-empt.
What you can buy today
Everything approved for this job, each with the maintenance price read from the seller's own page and the date it was read.
Last updated 2026-08-28 — trial registry and Drugs@FDA checked